A partnership between IRICoR and Ovarian Cancer Canada
For the past 10 years, IRICoR has targeted the best academia-based projects in order to translate them into innovative therapies that will benefit patients. So far, IRICoR has made close to 80 financings in high-quality projects, established more than 20 strategic partnerships with key players, both locally and internationally, towards initiation of 7 clinical trials in areas of unmet medical needs.
In the context of its LeadAction Competition Series, IRICoR is proud to launch with Ovarian Cancer Canada this new LeadAction Ovarian Cancer research competition (“Competition”).
Maximizing our impact
The goal of the Competition is to provide funding for innovative ovarian cancer research projects in order to accelerate the discovery of new treatments to be timely accessible to patients.
Investigators are invited to present projects that meet the following criteria:
- Foster major therapeutic advances for the benefit of patients;
- Address an unmet and clearly identified clinical need;
- Present great scientific and commercial potential aimed at showcasing research and innovation in Quebec and across the rest of Canada;
- Aim to develop biopharmaceutical compounds or biotherapies;
- Be situated between the hit-to-lead and the pre-clinical stages.
The Competition’s total budget allocation is $4M ($2M from IRICoR and $2M from Ovarian Cancer Canada).
A very important Competition
Ovarian cancer is the 5th most common cancer for women and is the most serious women’s cancer. According to the latest study from the Canadian Cancer Society, “an estimated 3,000 Canadian women will be diagnosed with ovarian cancer in 2019. An estimated 1,900 will die from the disease”*. These figures show that it is paramount to continue to advance research, particularly by setting up initiatives such as this Competition.
* Canadian Cancer Statistics Advisory Committee. Canadian Cancer Statistics 2019. Toronto, ON: Canadian Cancer Society; 2019. Available at: cancer.ca/Canadian-Cancer-Statistics-2019-EN (accessed January 31, 2020).
“We are thrilled to be joining in partnership with IRICoR to advance progress on ovarian cancer,” said Elisabeth Baugh, CEO of Ovarian Cancer Canada. “Collaborations like this one increase our capacity to go further and cover new ground in the science and understanding of the disease. There are immense opportunities to change the course we’ve been on with ovarian cancer through research and we’re excited to invest in improved outcomes for women diagnosed with this disease.”
“Hoping to have an impact on the life of women throughout the country, we felt that it was crucial to combine our efforts with a key player like Ovarian Cancer Canada to launch this LeadAction Ovarian Cancer Competition, which aims to subsidize scientific excellence and accelerate therapeutic innovations in ovarian cancer for the benefit of patients”, added Nadine Beauger, Chief Executive Officer of IRICoR.
The projects selected will be announced in the fall of 2020. Stay informed!
For more information, please go to the LeadAction Ovarian Cancer Competition page, here.